Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance

Leuk Lymphoma. 2007 Aug;48(8):1659-61. doi: 10.1080/10428190701474381.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Benzamides
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • Imatinib Mesylate
  • Karyotyping
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Male
  • Middle Aged
  • Piperazines / administration & dosage*
  • Pyrimidines / administration & dosage*
  • Retrospective Studies
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate